Clinical Trial Update: Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial [Phase 2]

View source ↗

Summary

Phase 2 pharmacogenetic testing study of rFVIIa analogue in patients with multiple exposure days in the Adept2 trial has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Bleeding Disorder
• Haemophilia with Inhibitors

Drugs mentioned

• Adept2 rFVIIa analogue (recombinant activated factor VII analogue)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Haemophilia A With Inhibitors | Phase 2 | Status: COMPLETED | Results posted: 2019-01-04